RESMED INC (RMD) earnings date, results and what the price requires
NYSE · SEC CIK 0000943819 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $1.46B | $383.1M | $2.64 | Filing |
| Mar 31, 2026 | Apr 30, 2026 | $1.43B | $398.7M | $2.74 | Filing |
| Dec 31, 2025 | Jan 29, 2026 | $1.42B | $392.6M | $2.68 | Filing |
| Sep 30, 2025 | Oct 30, 2025 | $1.34B | $348.5M | $2.37 | Filing |
| Jun 30, 2025 | Jul 31, 2025 | $1.35B | $380.0M | $2.58 | Filing |
| Mar 31, 2025 | Apr 23, 2025 | $1.29B | $365.0M | $2.48 | Filing |
| Dec 31, 2024 | Jan 30, 2025 | $1.28B | $344.6M | $2.34 | Filing |
| Sep 30, 2024 | Oct 24, 2024 | $1.22B | $311.4M | $2.11 | Filing |
What would RESMED INC have to report for its valuation to change?
At $242.23, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 14.7% a year, to $20.71. On that path the next quarter needs diluted EPS near $2.72, against $2.37 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 14.7% | 14.7% |
| EPS needed in final year | $20.71 | $20.71 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. RMD goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.